Tag: RNAtherapeutics
-
Novartis Licenses Abogen’s ABO2203 in $7.8B mRNA Deal
Novartis will pay Abogen $575 million upfront for worldwide rights to ABO2203, an mRNA-encoded CD19×CD3 T-cell engager, while securing options on additional RNA programs in a deal potentially worth approximately $7.8 billion.